HC Wainwright's Buy initiation comes with a $26 target that sits below the $30.50 consensus mean, making it a more conservative bullish entry on the diagnostics firm. New sell-side coverage can still aid visibility for a small-cap name. Test volume growth and path to profitability are the metrics that justify the rating versus the higher street average.
Biodesix (BDSX) has an average rating of buy and mean price target of $30.50, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Goldman Sachs on Friday downgraded Dutch lighting company Signify (LIGHT.AS) to neutral from buy, while maintaining its price target at 21 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Citi on Friday raised life-saving technology group Halma (HLMA.L) to buy from neutral and increased its price target to 46 pounds sterling from 37 pounds.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Riyad Capital on Thursday decreased the price target for Saudi Arabian medical services company and pharmacy operator Al-Dawaa Medical Services (SASE:4163) to 45 Saudi riyals from 50 riyals and kept its neutral rating.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)